Back Hepatitis C

Hepatitis C

AASLD 2013: 100% of Hard-to-treat Patients Cured with Sofosbuvir/Ledipasvir + Ribavirin or GS-9669

Interferon-free regimens of sofosbuvir and ledipasvir plus either ribavirin or GS-9669 taken for 12 weeks produced sustained response in 100% of treatment-experienced genotype 1 chronic hepatitis C patients with advanced liver fibrosis or cirrhosis, according to the latest findings from the ELECTRON trial presented yesterday at the 64th AASLD Liver Meeting in Washington, DC. A related analysis of previously untreated people without cirrhosis found that reducing treatment duration to 6 weeks led to relapses.

alt

AASLD 2013: Veterans Study Supports CDC Recommendation to Screen Baby Boomers for Hep C

A study of more than 5.5 million U.S. veterans presented at the 64thAASLD Liver Meeting this week in Washington, DC, found that 10% of those born between 1945 and 1965 tested positive for hepatitis C virus (HCV) -- compared with just 1%-2% of older or younger individuals -- providing support for recent recommendations that everyone in this age group should be screened for HCV regardless of risk factors.

alt

EACS 2013: HCV Reinfection Common Among HIV Positive Gay Men in Europe

A study found that 18% of HIV positive men acquired hepatitis C virus (HCV) a second time after clearing the virus, with some having third and fourth infections as well, according to findings from the European AIDS Treatment Network presented at the 14th European AIDS Conference this month in Brussels.

alt

AASLD 2013: Simeprevir + Sofosbuvir Produces High Sustained Response Rates for Hard-to-treat Patients

A 12-week all-oral combination of simeprevir plus sofosbuvir led to sustained virological response in 93% of genotype 1 prior null responders with mild-to-moderate liver fibrosis, working as well as a longer course of treatment or triple therapy including ribavirin, according to late-breaking findings from the COSMOS trial presented this week at the 64thAASLD Liver Meeting in Washington, DC. The study also showed that 100% of treatment-naive patients and null responders with advanced fibrosis or cirrhosis achieved early sustained response at 4 weeks post-treatment using the same dual regimen.

alt

EACS 2013: Faldaprevir Demonstrates Good Early Response in Genotype 1 HIV/HCV Coinfection

The HCV protease inhibitor faldaprevir added to pegylated interferon and ribavirin increased the likelihood that HIV/HCV co-infected people would achieve a sustained response at 4 weeks after completing treatment, according to a report at the 4th European AIDS Conference last week in Brussels.

alt

AASLD Liver Meeting Starts this Weekend in Washington, DC

The American Association for the Study of Liver Diseases (AASLD) annual Liver Meeting gets underway this Friday, running November 1-5 at the Walter E. Washington Convention Center in Washington, DC. The highlight of this year's meeting will be numerous presentations on next-generation direct-acting antivirals (DAAs) for hepatitis C, now in late stages of development, both as interferon add-ons and in interferon-free regimens.

alt

EACS 2013: Simeprevir with Interferon Effective for Genotype 1 HIV/HCV Coinfected People

Adding the direct-acting hepatitis C drug simeprevir to pegylated interferon and ribavirin produced high response rates for HIV positive people coinfected with HCV genotype 1, researchers reported at the 14th European AIDS Conference this week in Brussels. Particularly impressive was a 57% sustained response rate for prior null responders. Another study showed simeprevir to be active against HCV genotype 4 in monoinfected patients.

alt

FDA Advisory Committee Gives Positive Opinions on HCV Drugs Simeprevir and Sofosbuvir

The Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) this week gave unanimous recommendations for approval of 2 next-generation direct-acting antivirals for hepatitis C, Janssen's simeprevir (formerly TMC435) and Gilead Science's sofosbuvir (formerly GS-7977 and PSI-7977).

alt

EACS 2013: New Drugs Will Bring Revolution in Hepatitis C Treatment

The advent of direct-acting antiviral agents can rightly be described as a revolution in treatment for chronic hepatitis C, but potential challenges remain including drug interactions and cost, Heinrich Wedemeyer told participants during a plenary session at the 14thEuropean AIDS Conference (EACS 2013) this week in Brussels.

alt